Head to Head Contrast: Lipella Pharmaceuticals (LIPO) and The Competition

Lipella Pharmaceuticals (NASDAQ:LIPO) is one of 1,042 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Lipella Pharmaceuticals to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, earnings, dividends, profitability and valuation.

Insider & Institutional Ownership

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 37.0% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Lipella Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals’ competitors have a beta of 1.00, indicating that their average share price is 0% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Lipella Pharmaceuticals and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0	0	1	0	3.00
Lipella Pharmaceuticals Competitors	7516	20707	48155	1169	2.55

Lipella Pharmaceuticals currently has a consensus price target of $2.00, suggesting a potential downside of 39.21%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.61%. Given Lipella Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Lipella Pharmaceuticals has less favorable growth aspects than its competitors.

Profitability

This table compares Lipella Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-817.16%	-172.07%	-141.17%
Lipella Pharmaceuticals Competitors	-3,452.97%	-255.29%	-30.69%

Valuation & Earnings

This table compares Lipella Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lipella Pharmaceuticals	$450,000.00	-$4.62 million	-5.48
Lipella Pharmaceuticals Competitors	$1.71 billion	$155.16 million	-7.51

Lipella Pharmaceuticals’ competitors have higher revenue and earnings than Lipella Pharmaceuticals. Lipella Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Lipella Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.